Real-world clinical experience of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in hypertension: The EXCITE study

Current Medical Research and Opinion

Volumn 30, Issue 10, 2014, Pages 1937-1945

  Sison, Jorge ^a   Assaad Khalil, Samir Helmy ^b   Najem, Robert ^c   Kitchlew, Asad Riaz ^d   Cho, Belong ^e   Ueng, Kwo Chang ^f   Shete, Abhijit ^g   Knap, Ditte ^g  

^a Manila Adventist Medical Center   (Philippines)

^b ALEXANDRIA UNIVERSITY   (Egypt)

^c LEBANESE UNIVERSITY   (Lebanon)

^d PAKISTAN INSTITUTE OF MEDICAL SCIENCES   (Pakistan)

^e Seoul National University College of Medicine   (South Korea)

^f CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^g NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Amlodipine valsartan; Amlodipine valsartan hydrochlorothiazide; Hypertension; Single pill combinations

Indexed keywords

AMLODIPINE PLUS HYDROCHLOROTHIAZIDE PLUS VALSARTAN; AMLODIPINE PLUS VALSARTAN; AMLODIPINE; AMLODIPINE, VALSARTAN DRUG COMBINATION; ANTIHYPERTENSIVE AGENT; DRUG COMBINATION; HYDROCHLOROTHIAZIDE; TETRAZOLE DERIVATIVE;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FEMALE; HEART DISEASE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MULTICENTER STUDY; PERIPHERAL EDEMA; SYSTOLIC BLOOD PRESSURE; ASIA; BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; DRUG EFFECTS; DRUG MONITORING; HEART FAILURE; METHODOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; ASIA; BLOOD PRESSURE; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DRUG MONITORING; FEMALE; HEART FAILURE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RESEARCH DESIGN; TETRAZOLES; TREATMENT OUTCOME;

EID: 84921857177     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2014.942415     Document Type: Article

References (30)

1. Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2224-60
2. Ibrahim MM, Damasceno A. Hypertension in developing countries. Lancet 2012;380:611-19
3. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217-23
4. WHO High Blood Pressure Fact Sheet, World Health Day 2013. Available at: http://www.euro.who.int/-data/assets/pdf-file/0004/185917/Fact-sheet-World-Health-Day-2013-Eng-final.pdf [Last accessed 19 August 2013]
5. Danaei G, Finucane MM, Lin JK, et al; for the Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Pressure). National, regional, and global trends in systolic blood pressure since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5.4 million participants. Lancet 2011;377:568-77
6. Chiang CE, Wang TD, Li YH, et al. 2010 guidelines of the Taiwan Society of Cardiology for the management of hypertension. J Formos Med Assoc 2010;109:740-73
7. Wang ZW, Wang X, Wang W, et al. The current situation of blood pressure control and the influencing factors on hypertensive patients in residential communities of China. Chin J Epidemiol 2012;33:903-6
8. Sison J, Arceo LP, Trinidad E, et al. Philippine Heart Association - Council on Hypertension Report on Survey of Hypertension and Target Organ Damage (PRESYON 2-TOD). A report on prevalence of hypertension, awareness, treatment profile and control rate. Phil J Cardiol 2007;35:1-9
9. Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada and the United States. Hypertension 2004;43:10-17
10. Pereira M, Lunet N, Azevedo A, et al. Differences in prevalence, awareness, treatment and control of hypertension between developing and developed countries. J Hypertens 2009;27:963-75
11. Burnier M, Brown RE, Ong SH, et al. Issues in blood pressure control and the potential role of single-pill combination therapies. Int J Clin Pract 2009;63:790-8
12. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. J Hypertens 2013;31:1281-357
13. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003;42:1206-52
14. Smith TR, Philipp T, Vaisse B, et al. Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studies. J Clin Hypertens 2007;9:355-64
15. Philipp T, Smith TR, Glazer R, et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther 2007;29:563-80
16. Allemann Y, Fraile B, Lambert M, et al. Efficacy of the combination of amlodipine and valsartan in hypertensive patients uncontrolled on previous monotherapy: The EX-FAST Study. J Clin Hypertens 2008;10:185-94
17. Destro M, Luckow A, Samson M, et al. Efficacy and safety of amlodipine/valsartan compared with amlodipine monotherapy in patients with stage 2 hypertension: a randomized, double-blind, multicenter study: the EX-EFFeCTS study. J Am Soc Hypertens 2008;2:294-302
18. Flack JM, Calhoun DA, Satlin L, et al. Efficacy and safety of initial combination therapy with amlodipine/valsartan compared with amlodipine monotherapy in black patients with stage 2 hypertension: the EX-STAND study. J Hum Hypertens 2009;23:479-89
19. Calhoun DA, Lacourcière Y, Chiang YT, et al. Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide. A randomized clinical trial. Hypertension 2009;54:32-9
20. Calhoun DA, Crikelair NA, Yen J, et al. Amlodipine/valsartan/hydrochlorothiazide triple combination therapy in moderate/severe hypertension: secondary analyses evaluating efficacy and safety. Adv Ther 2009;26:1012-23
21. Chazova IE, Dongre N, Vigdorchik AV. Real-life safety and effectiveness of amlodipine/valsartan combination in the treatment of hypertension. Adv Ther 2011;28:134-49
22. Karpov Y, Dongre N, Vigdorchik A, et al. Amlodipine/valsartan single-pill combination: a prospective, observational evaluation of the real-life safety and effectiveness in the routine treatment of hypertension. Adv Ther 2012;29:134-47
23. Suh DC, Kim CM, Choi IS, et al. Trends in blood pressure control and treatment among type 2 diabetes with comorbid hypertension in the United States: 1988-2004. J Hypertens 2009;27:1908-16
24. Glandt M, Bloomgarden ZT. Hypertension in diabetes: treatment considerations. J Clin Hypertens 2011;13:314-31
25. Rydé n L, Grant PJ, Anker SD, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2013;34:3035-87
26. National Institute for Health and Clinical Excellence. Clinical Guideline 127 Hypertension: clinical management of primary hypertension in adults. Issue date: August 2011. Available at: www.nice.org.uk/guidance/CG127 [Last accessed 11 December 2013]
27. Yiannakopoulou EC, Papadopulos JS, Cokkinos DV, et al. Adherence to antihypertensive treatment: a critical factor for blood pressure control. Eur J Cardiovasc Prev Rehabil 2005;12:243-9
28. Halpern MT, Vincze G, Stewart WF, et al. Compliance with hypertension therapy and long-term cardiovascular outcomes. J Hypertens 2006;24(Suppl 4):S154-5
29. Halpern MT, Vincze G, Stewart WF, et al. Persistence with hypertension therapy and long-term cardiovascular outcomes. J Hypertens 2006;24(Suppl 4):S182-3
30. Sokol MC, McGuigan KA, Verbrugge RR, et al. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005;43:521-30